Should You Trim Or Add To Your Viking Therapeutics Position?
For questions about this article or underlying research, email help@trefis.com.
Viking Therapeutics (VKTX) sells no product yet, but the market values it at $3.45 billion, largely a bet on VK2735, its obesity drug. The stock lost 28.3% over the past year while the S&P 500 returned 11.7%. Holders who add now are trusting that VK2735 works in its Phase 3 trials and that Viking’s money lasts until those results arrive. How long can Viking keep paying for those trials from the cash it holds?

How Long Can Viking Keep Spending At This Pace?
Viking’s cash after debt covers about a year and a half of spending at last year’s rate, and less at its latest pace. The company ended September 2026 with $960 million in cash and short-term investments, or $705 million after subtracting its debt. Its operations used $463 million of cash over the twelve months to September. At the September quarter’s pace, its cash after debt would last about 15 months.
That spending has risen in each of the three quarters since the December 2025 quarter. Viking used $138 million of cash in the September 2026 quarter, up from $85.3 million in the December 2025 quarter. Each further rise shortens the time its cash lasts.
Viking’s losses have grown alongside its spending. Its operating loss over the twelve months to September was $649 million, up from $275 million a year earlier. The S&P 500 turns 18.9% of its sales into operating profit, while Viking has no sales yet to set against its costs.
Viking’s VK2735 Is Still In Phase 3 Trials
Because VK2735 has not yet produced Phase 3 results, whether the drug works remains an open question. In its October 28, 2026 release, Viking said its VANQUISH Phase 3 trials of VK2735, given as an injection under the skin, continue to advance, and that its SUNRISE Phase 3 trials of an oral form of the drug have started.
Viking does have good news on VK2735 from a separate study. The company announced positive top-line results from a study of VK2735 maintenance dosing and has begun a second part of that study. A second drug, VK3019, is further behind, with its Phase 1 study nearing completion. Taken together, that makes the Phase 3 trials, more than the cash, the open question for anyone holding Viking stock.
What Are Investors Paying For In Viking Stock?
Investors are paying mostly for Viking’s drugs, and above all for VK2735. After subtracting its net cash, the market puts a value of about $2.74 billion on drugs that have yet to bring in any sales. The usual price tag does not apply here. The S&P 500 trades at 21.9 times its earnings, but Viking has losses rather than earnings, so a P/E for Viking is not meaningful. If VK2735 falls short in Phase 3, it is the value the market puts on the drugs, not the cash, that holders would have at stake.
Viking stock has also fallen much further than the broader market during past shocks. In the 2022 inflation shock and Fed tightening, shares fell 57% from peak to low, against 24% for the SPY fund that tracks the S&P 500. During the 2025 tariff shock, the stock fell 38%, against 19% for the same fund.
So far, Viking’s cash covers its spending, though that spending keeps rising. VK2735 has positive maintenance dosing results, but there is no Phase 3 answer yet. Until the VANQUISH results arrive, the cash Viking spends each quarter, next reported for the three months ending December 31, 2026, is the number to watch.
Beyond VKTX: A Systematic Way To Invest
Before you decide on VKTX, consider a better choice. Since its September 2020 launch, the Trefis High Quality (HQ) Portfolio has returned 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000, without betting on one stock.
Spot an error or want more like this? Tell us in 10 seconds.